The Valley Desk

Clinical trial reportCancerPublished

Talquetamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1/2 MonumenTAL-1 study

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Clinical trial report
Venue
Cancer
Published
Subject terms
Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Antibodies, Bispecific; Quality of Life; Adult; Aged; Aged, 80 and over; Middle Aged; Female; Male; Patient Reported Outcome Measures
PubMed ID
40631904
PubMed Central ID
PMC12239699
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal